Epidermal growth factor receptor (EGFR) inhibitors, panitumumab, and cetuximab used to treat metastatic colorectal cancer expressing wild-type KRAS show a beneficial effect in only 10–20% of patients [64,65]. This evidence concerns the gene EGFR and metastatic colorectal cancer.